20
Participants
Start Date
July 16, 2012
Primary Completion Date
February 28, 2023
Study Completion Date
February 28, 2023
sorafenib tosylate
Given PO
placebo
Given PO
laboratory biomarker analysis
Correlative studies
New York University Langone Medical Center, New York
New York Presbyterian-The University Hospital of Columbia and Cornell, New York
University of Pittsburgh, Pittsburgh
Lombardi Comprehensive Cancer Center at Georgetown University, Washington D.C.
Emory University, Atlanta
Vanderbilt University, Nashville
Cleveland Clinic Foundation, Cleveland
University of Michigan University Hospital, Ann Arbor
Northwestern University, Chicago
Ochsner Clinic Foundation, New Orleans
Integris-Baptist Medical, Oklahoma City
Baylor College of Medicine, Houston
The Methodist Hospital Research Institute, Houston
Jonsson Comprehensive Cancer Center, Los Angeles
University of Alabama, Birmingham
University of Colorado, Denver
Mount Sinai Hospital, Hartford
Johns Hopkins University, Baltimore
Lahey Clinic Medical Center, Burlington
University of Nebraska Medical Center, Omaha
University of Pennsylvania Health System, Cherry Hill
Collaborators (1)
Bayer
INDUSTRY
Jonsson Comprehensive Cancer Center
OTHER